Background. Small intestinal ulcers are frequent complications of therapy with nonsteroidal antiinfl ammatory drugs (NSAIDs). We present here a genetic defi ciency of eicosanoid biosynthesis that illuminates the mechanism of NSAID-induced ulcers of the small intestine. Methods. Eicosanoids and metabolites were measured by isotope dilution with mass spectrometry. cDNA was obtained by reverse transcription and sequenced following amplifi cation with RT-PCR. Results. We investigated the cause of chronic recurrent small intestinal ulcers, small bowel perforations, and gastrointestinal blood loss in a 45-year-old man who was not taking any cyclooxygenase inhibitor. Prostaglandin metabolites in urine were signifi cantly depressed. Serum thromboxane B 2 (TxB 2 ) production was 4.6% of normal controls (P < 0.006), and serum 12-HETE was 1.3% of controls (P < 0.005). Optical platelet aggregation with simultaneous monitoring of ATP release demonstrated absent granule secretion in response to ADP and a blunted aggregation response to ADP and collagen, but normal response to arachidonic acid (AA). LTB 4 biosynthesis by ionophore-activated leukocytes was only 3% of controls, and urinary LTE 4 was undetectable. These fi ndings suggested defi cient AA release from membrane phospholipids by cytosolic phospholipase A 2 -α (cPLA 2 -α), which regulates cyclooxygenase-and lipoxygenase-mediated eicosanoid production by catalyzing the release of their substrate, AA. Sequencing of cPLA 2 -α cDNA demonstrated two heterozygous nonsynonymous single-base-pair mutations: Ser111Pro (S111P) and Arg485His (R485H), as well as a known single nucleotide polymorphism (SNP), Lys651Arg (K651R). Conclusions. Characterization of this cPLA 2 -α defi ciency provides support for the importance of prostaglandins in protecting small intestinal integrity and indicates that loss of prostaglandin biosynthesis is suffi cient to produce small intestinal ulcers.
Introduction
Small intestinal ulcers are a well-established consequence of the use of nonsteroidal antiinfl ammatory drugs (NSAIDS). [1] [2] [3] [4] [5] The pharmacological property shared by all the NSAIDs is inhibition of the cyclooxygenase enzymes that synthesize prostaglandins. 6 Considerable evidence indicates that inhibition of prostaglandin biosynthesis contributes to the small intestinal ulcers caused by NSAIDs. Other studies, however, have suggested that cyclooxygenase-independent effects of NSAIDS on the small intestine also are required for ulcer formation. 7, 8 One postulated off-target mechanism has been topical injury to enterocytes by the NSAIDs during absorption of the drugs. The extent to which such topical cyclooxygenase-independent actions are required to produce small intestinal ulcers, however, has been unclear. To address whether inhibition of prostaglandin biosynthesis alone is suffi cient to cause small intestinal ulcers, we present here the investigation of an inherited defi ciency of prostaglandin biosynthesis that is associated with severe small intestinal ulcer disease with attendant diaphragm-like constrictions.
Methods

Study conduct
Informed consent was obtained from all participants after study approval by the Vanderbilt University Institutional Review Board. The patient was admitted to the Clinical Research Center at Vanderbilt University Medical Center (VUMC) for 7 days, during which time all medications were withheld. Consecutive 24-h urine collections were obtained before phlebotomy, which was subsequently performed daily after an overnight fast. Blood specimens from family members were obtained remotely and shipped to our facility. Healthy male volunteers who reported no use of aspirin or NSAIDs in the preceding 2 weeks served as controls. 2 , PGD 2 , PGI 2 , and TxA 2 Urinary metabolites of thromboxane A 2 (11-dehydrothromboxane B 2 , 11-dTxB 2 ), prostacyclin (2,3-dinor-6-keto-prostaglandin F 1α , PGI-M), prostaglandin D 2 (9α,11β-dihydroxy-15-oxo-2,3,18,19-tetranorprost-5-ene-1,20-dioic acid, PGD-M), and prostaglandin E 2 (11α-hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid, PGE-M) were assayed using mass spectrometry as described previously [9] [10] [11] [12] from separate 24-h urine collections on different days.
Urinary metabolites of PGE
Urinary LTE 4
LTE 4 was analyzed by a previously published LC/MS/ MS method 13 with minor modifi cations.
Platelet-derived (serum) thromboxane B 2 (TxB 2 ) and 12-hydroxyeicosatetraenoic acid (12-HETE)
Blood obtained from the patient on multiple days was drawn into a glass container and allowed to clot by incubating at 37°C for 45 min. The serum layer was collected after centrifugation and TxB 2 was assayed by GC/ECI/MS as described previously. 14,15 12-HETE was assayed by LC/APCI/MS/MS using a silica HPLC column as described previously. 16 
TxB 2 production in washed platelets
Platelets were gel-fi ltered as described previously: 17 100 μl of the platelet suspension (600 000 cells/μl) was incubated with [ 2 H 8 ]AA 2 μM at 37°C for 15 min. After the reaction was stopped, TxB 2 was purifi ed, derivatized, and analyzed by GC/ECI/MS.
Immunoblotting of cPLA 2 -a protein
Western blot analysis of protein was performed using rabbit anti-cPLA 2 (Cell-Signaling: Danvers, MA, USA), goat anti-COX-1 (Santa Cruz Biotechnology: Santa Cruz, CA, USA), or goat antiactin (Santa Cruz) primary antibodies and horseradish peroxidase-coupled secondary antibodies (Santa Cruz: Santa Cruz, CA, USA). Band intensity was quantifi ed using image analysis software (Quantity One v4.3.; Bio Rad: Hercules, CA, USA).
Platelet aggregation
Citrated platelet-rich plasma from peripheral venous blood from the patient and control volunteers was used to assess turbidimetric platelet aggregation induced by adenosine diphosphate (ADP), collagen, or AA. Platelet counts were adjusted to 2.6-2.8 × 10 8 cells/ml before aggregation. Simultaneous adenosine triphosphate (ATP) secretion was quantifi ed by monitoring luminescence produced by luciferase using an optical platelet aggregometer (Chronolog: Havertown, PA, USA).
Lymphoblast separation and culture
Lymphoblasts were separated from whole blood using Lymphosep lymphocyte separation medium (MP Biochemicals: Solon, OH, USA) and cultured after addition of cyclosporine as described by the manufacturer.
PLA 2 activity
Platelets obtained on 2 different days from the patient and from two volunteers were frozen as platelet-rich plasma (PRP) in citrate at −80°C. Thawed platelets or fresh cultured lymphoblasts were washed and resuspended in buffer [HEPES 10 mM, sucrose 0.34 M glycerol 10%, ethylenediaminetetraacetic acid (EDTA) 1 mM, pH 7.75] with a protease inhibitor cocktail. Whole cell lysate was obtained by sonication of cell suspension followed by brief centrifugation at 10 000 g. Dithiothreitol 1 mM was added to prevent oxidative enzyme degradation. PLA 2 activity was measured from whole cell lysate (50 μg protein) with a radiolabeled substrate, L-3-phosphatidylcholine, 1-stearoyl-2-[1-
14 C] arachidonyl ( 14 C-SAPC; 450 pmol, 55 000 dpm), under conditions described by Leslie and Gelb 18 [NaCl 150 mM, bovine serum albumin (BSA) 1 mg/ml, HEPES 42 mM, CaCl 2 10 mM, pH 7.5]. Substrate hydrolysis was measured over a time period demonstrating linear kinetics. Reactions were stopped by addition of chloroform : methanol 2 : 1, and the extracted lipids were separated by thin-layer chromatography. Residual substrate and hydrolyzed arachidonic acid were quantifi ed by analyzing radioactivity using a Bioscan AR-200 imaging scanner (Biosean: Washington, DC, USA).
cPLA 2 -a cDNA sequencing
Oligonucleotide primer sequences were those previously published. 19 cDNA was obtained by reverse transcription [Invitrogen Superscript III and Elongase kits (Invitrogen: Carlsbad, CA, USA)] using total RNA isolated with a whole blood RNA collection system (Qiagen PAXgene: Valencia, CA, USA) as a template and oligo dT as a primer. Following reverse transcriptasepolymerase chain reaction (RT-PCR) amplifi cation using primer 1 and primer 2 oligonucleotide primers, DNA sequencing was done using primers 1-14 with Applied Biosystems Big Dye v3.1 (Applied Biosystems: Foster City, CA, USA). All the variants detected in RT-PCR products were confi rmed by direct sequencing of the corresponding segments of genomic DNA.
Statistics
Normally distributed continuous variables were compared using a t test with Welch's correction applied when variances were different. Mann-Whitney U test was used for comparison of continuous variables without normal distribution. PLA 2 activity was compared using two-way analysis of variance (ANOVA). All analyses were performed using Graphpad Prism 4.0 software for MS Windows (Graphpad: La Jolla, CA, USA). Means are reported ± standard deviation unless otherwise specifi ed.
Results
Clinical fi ndings
A 45-year-old Caucasian American man of Italian descent presented with a lifelong history of occult gastrointestinal blood loss, chronic anemia, iron defi ciency, and frequent bouts of abdominal pain as a child and young adult. Repeated episodes of acute gross gastrointestinal bleeding late in his fourth decade and multiple episodes of small bowel perforation required fi ve surgical interventions between 38 and 45 years of age. Surgical exploration of the small intestine and intraoperative endoscopy revealed multiple recurrent small intestinal ulcerations. Histological specimens of the ileum and jejunum revealed multiple small, well-demarcated ulcers with minimal surrounding infl ammation. Stenotic ileal web formations were also described proximal to several ulcers. Misoprostol (800 μg daily), an oral prostaglandin E 1 analogue, had been initiated with subsequent resolution of anemia for a period of 27 months until gastrointestinal (GI) bleeding recurred.
Colonoscopy and esophagogastroduodenoscopy had been performed on multiple occasions and always had been normal. Mesenteric arteriograms, gastrin secretion, and laboratory and histological evaluation for celiac sprue and infl ammatory bowel disease were all normal. He denied having had diarrhea, nausea, vomiting, or constipation. He had no history of bruising or nongastrointestinal bleeding symptoms or severe or recurrent infections.
A clear cell renal carcinoma (Furman grade II) was resected at age 40. A brief period of mild wheezing in early childhood was reported without subsequent respiratory complaints. A shellfi sh allergy causing urticaria was reported. Medications included iron sulfate and a multivitamin in addition to misoprostol. Use of nonsteroidal antiinfl ammatory and corticosteroid medications was specifi cally denied.
The patient's father had died of multiple myeloma, and varying malignancies were reported in second-and third-degree relatives. No renal malignancy was reported in family members. There was no family history of ulcers.
Physical examination revealed a well-developed male. Blood pressure was normal. A 2/6 systolic murmur was heard at the left sternal border. His abdomen was notable for multiple well-healed surgical scars. Physical examination was otherwise unremarkable.
An electrocardiogram and an echocardiogram were normal. Ultrasonography demonstrated normal kidneys with evidence of prior partial resection. Blood cell counts, electrolytes, renal, and liver function values were normal.
Urinary metabolites of PGE 2 , PGD 2 , PGI 2 , and TxA 2
Quantifi cation of the patient's urinary prostanoid metabolites demonstrated reduced levels compared with reference values (Table 1 ). The patient's mother and sister did not have reduced urinary prostanoid metabolite levels.
Platelet-derived (serum) TxB 2 and 12-HETE
The fi nding that 11d-TxB 2 excretion was reduced by 84.1% led to the hypothesis that TxA 2 biosynthesis by the platelets was impaired. This function was assessed by measurement of TxB 2 released into the serum during blood clotting, which is derived almost entirely from platelets. 20 The patient's mean serum TxB 2 was reduced by 95.9% (Table 2) , which could refl ect pharmacological inhibition of platelet COX-1, COX-1 defi ciency, or lack of the COX-1 substrate, AA (Fig. 1) . A genetic defi ciency of thromboxane synthase seemed unlikely because of the depressed biosynthesis of other prostanoids. To distinguish between these possibilities, the product of the platelet 12-lipoxygenase, 12-HETE, was measured in serum; 12-HETE should be unchanged or increased with pharmacological or genetic impairment of COX-1 catalytic activity. The level of 12-HETE in the patient's serum was decreased by 97.8% (see Table 2 ), a fi nding consistent with an almost complete absence of the release of AA during platelet activation. The patient's mother and sister exhibited intermediate values for platelet-derived TxB 2 and 12-HETE that were below or at the lower end of the normal range. 
Urinary leukotriene E 4 (LTE 4 )
LTE 4 was below the limit of detection of 1 pg/ml in the patient's urine, whereas the range of normal values is 19-60 pg/ml.
Whole blood leukotriene B 4 (LTB 4 )
LTB 4 produced by whole blood activated by calcium ionophore from the patient measured 7.2 ± 3.3 ng/ml; whole blood from healthy volunteers produced 243.7 ± 22.6 ng/ml LTB 4 (see Table 2 ). 
Platelet aggregation
Platelet function was assessed by monitoring platelet aggregation and dense granule secretion in response to stimulation by ADP or collagen. ADP 5 μM and collagen 2 μg/ml were the lowest doses of these reagents inducing granule secretion in all controls. ADP 5 μM induced a diminished aggregation of the patient's platelets compared with controls (n = 6): mean, 73.0 ± 8.29 versus 92.67 ± 11.91 maximum % aggregation (P < 0.005). Collagen 2 μg/ml also induced less aggregation in the patient, inducing a mean % maximal aggregation of 61.0 ± 14.8 versus 95.33 ± 15.2 in controls (P < 0.005). Notably, ATP release, which is a measure of dense granule secretion in response to ADP, was completely absent in the patient's platelets as opposed to controls, which released a mean 0.88 ± 0.33 nmol ATP (P = 0.001). ATP release in response to collagen 2 μg/ml also was decreased signifi cantly in the patient versus controls: mean, 0.16 ± 0.032 versus 1.1 ± 0.34 nmol (P = 0.002). Normal aggregation and ATP release were observed in the patient's PRP with addition of AA 250 μM.
cPLA 2a protein in platelets
Immunoblotting for cPLA 2α in the patient's platelets detected protein of expected molecular weight but in diminished quantity (approximately 38% of control). COX-1 was detected in equal amounts in the patient and controls.
PLA 2 activity
The patient's mean total PLA 2 activity in sonicated platelets represented 27.2% of the activity in controls, with mean activity 0.77 ± 0.32 vs. 2.83 ± 0.47 pmol/min/ 50 μg protein (P < 0.0005) in controls. [K651R] ). The patient was heterozygous for all three transitions, and no changes were found in the 3′ or 5′ untranslated regions. Sequencing of cPLA 2α cDNA from the patient's mother and sister showed that the mother was heterozygous for the p. [K651R] transitions on the other allele. All the variants detected in cDNA products were confi rmed by direct sequencing of the corresponding segments of genomic DNA.
Discussion
We have characterized a novel functional defi ciency of cPLA 2 -α resulting from compound heterozygosity for two rare variants (p.
[S111P] and p.
[R485H]) in a patient with ulcers and diaphragm-like strictures of the small intestine, platelet dysfunction, and globally decreased eicosanoid production. Our fi ndings indicate that cPLA 2 -α provides substrate for virtually all eicosanoid biosynthesis by human platelets, leukocytes, and the cells from which cysteinyl leukotrienes are derived, and also indicate that products of this phospholipase contribute importantly to maintaining the integrity of the small intestine.
Concerted evidence supports a causal relationship between the observed mutations and the phenotype. Both the c.[331T > C] and the c.[1454 G > A] are missense mutations. Each of these mutations is rare; neither was found in the population of 418 DNA multiethnic samples that we analyzed, and neither was reported in the NCBI SNP database. These rare mutations are associated with a rare biochemical phenotype; no evidence for a block in eicosanoid biosynthesis at the level of cPLA 2 -α has previously been reported in humans. The clinical phenotype of early onset of iron-defi ciency anemia resulting from non-drug-related small bowel ulcers also is very uncommon. The biochemical phenotype of impaired biosynthesis of both TxB 2 and 12-HETE in platelets cosegregates with the mutations in the family, with the compound heterozygosity for the mutations in the patient yielding virtually complete absence of their biosynthesis and with the expected intermediate reduction in biosynthesis in the family members who are heterozygous for a single mutant allele. Each of the amino acids affected by the mutations is conserved across species, and molecular modeling implies that conformational changes should result from the mutations. 19 The mechanism of NSAID-induced small intestinal ulcers is informed by the fi nding that severe ulcers and diaphragmatic constrictions of the small intestine result from a genetic defi ciency of prostaglandin biosynthesis. This fi nding supports a conclusion that loss of cyclooxygenase products is suffi cient to cause complicated small intestinal ulcers. As the loss of prostaglandin biosynthesis is genetic, it is not possible to attribute this enteropathy to off-target effects of drugs.
The fact that reduced prostaglandin biosynthesis alone can cause small intestinal ulcers of course does not preclude modifying factors that could infl uence the development of small intestinal ulcers in a particular patient. Indeed, there is considerable interindividual variation in the extent of small intestinal pathology produced by an NSAID. It is known, for example, that bile and intestinal microfl ora can modify the small intestinal response to NSAIDs. Pharmacokinetic differences would be predicted to affect the response to an NSAID, as would genetic differences in the prostaglandin biosynthetic enzymes and signaling molecules. Indeed, it could be hypothesized that heterozygous loss of a functional cPLA 2 -α allele would exaggerate the response to an NSAID.
Although small intestinal ulcers unrelated to use of NSAIDs or enteric-coated drugs are uncommon, a number of such patients have been reported.
2 CPLA 2 -α defi ciency may be considered in the molecular differential diagnosis of such ulcers, particularly those with onset early in life. The fi nding of jejunoileal ulcers as a phenotype of cPLA 2 -α defi ciency identifi es a biochemical pathway linked to this disease and affords a hypothesis that loss of function at other steps in the biosynthetic or signaling pathways for the relevant prostaglandin could yield a similar phenotype. The small intestinal sequelae of cPLA 2 -α defi ciency also become relevant in consideration of the consequences of employing selective cPLA 2 -α inhibitors as therapeutic agents.
Nonselective COX inhibition by NSAIDs causes gastroduodenal ulceration with high morbidity and mortality. 21 In contrast, this patient with cPLA 2 -α defi ciency suffered from severe ulcer disease exclusively of the ileum and jejunum; no gastroduodenal ulcers had been detected on repeated upper intestinal endoscopies. This restriction of ulcer disease to the jejunum and ileum has been characteristic of other reported patients with NSAID-independent small intestinal ulcers. 2, 4 The selectivity for the jejunum and ileum could result from cPLA 2 -α serving as the key phospholipase providing AA substrate in these portions of the small intestine, in contrast with a different phospholipase releasing AA for biosynthesis of the PGs that protect the stomach 22, 23 and duodenum from ulceration. Alternatively, lipoxygenase-derived products of AA may be more important contributors to ulcer formation in the stomach and duodenum than in the ileum and jejunum. LTB 4 concentrations were markedly increased in the fundic mucosa of rats that received indomethacin compared with controls, and 5-lipoxygenase inhibitors have been shown to mitigate NSAID-induced gastric and intestinal lesions. 24 Notably, this attenuation was more profound in gastric mucosa, which demonstrated 95.4% and 98.8% reductions in lesion number and size, respectively, compared with 72.5% and 86.9% reductions in the small intestine. No such increase in gastric leukotriene products would be expected in the absence of cPLA 2 -α. Moreover, the fi ndings in this patient with cPLA 2 -α defi ciency indicate that NSAID-induced increases in leukotrienes cannot be implicated in the causality of the small intestinal ulcers produced by these drugs.
A concerted body of evidence indicates that cPLA 2 -α is the principal and rate-limiting phospholipase responsible for initiating eicosanoid biosynthesis in the platelet. [25] [26] [27] [28] Our fi ndings strongly support the concept that in the intact platelet, cPLA 2 -α initiates the signalinginduced release of virtually all the AA that is substrate for both the COX-1-and 12-lipoxygenase-derived pathways. Analysis of eicosanoid biosynthesis in activated platelets, therefore, provides an optimal biochemical phenotype with which to detect heterozygosity. LTB 4 biosynthesis by blood leukocytes also is derived almost entirely via the cPLA 2 -α pathway.
cPLA 2 -α (-/-) mice [28] [29] [30] [31] [32] [33] manifest platelet dysfunction and have small bowel ulcers that are much less severe than in the patient lacking this enzyme. These knockout mice have cardiac hypertrophy, which is not evident in the patient.
In conclusion, we have characterized compound heterozygous CPLA 2 -α variants that cause platelet dysfunction and are associated with multiple recurrent small bowel ulcers. Characterization of this defi ciency informs the mechanism of NSAID-induced small intestinal ulcers and has the potential for elucidating the biology and pathophysiology of cPLA 2 -α. These fi ndings also have signifi cant implications for the safety and effectiveness of pharmacological inhibition of the cPLA 2 -α enzyme.
